The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1O44IP     [(3E,8R,9S,10R,13S,14S,17R)- 13-ethyl-17...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NORGESTIMATE


Psychiatry related information on NORGESTIMATE


High impact information on NORGESTIMATE


Chemical compound and disease context of NORGESTIMATE


Biological context of NORGESTIMATE


Anatomical context of NORGESTIMATE


Associations of NORGESTIMATE with other chemical compounds


Gene context of NORGESTIMATE


Analytical, diagnostic and therapeutic context of NORGESTIMATE


  1. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. Grinspoon, S.K., Friedman, A.J., Miller, K.K., Lippman, J., Olson, W.H., Warren, M.P. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  2. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Cole, J.A., Norman, H., Doherty, M., Walker, A.M. Obstetrics and gynecology (2007) [Pubmed]
  3. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Davis, A., Godwin, A., Lippman, J., Olson, W., Kafrissen, M. Obstetrics and gynecology. (2000) [Pubmed]
  4. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. Lucky, A.W., Henderson, T.A., Olson, W.H., Robisch, D.M., Lebwohl, M., Swinyer, L.J. J. Am. Acad. Dermatol. (1997) [Pubmed]
  5. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. Strokosch, G.R., Friedman, A.J., Wu, S.C., Kamin, M. The Journal of adolescent health : official publication of the Society for Adolescent Medicine (2006) [Pubmed]
  6. Determination of circular dichroism and ultraviolet spectral parameters of norgestimate- and other Delta(4)-3-ketosteroid oxime isomers via normal phase HPLC method. Szentesi, A., Gergely, A., Horváth, P., Mahó, S., Mátyus, P., Szász, G. Current medicinal chemistry. (2001) [Pubmed]
  7. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde, M.I., Balfour, J.A. Drugs (1995) [Pubmed]
  8. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Devineni, D., Skee, D., Vaccaro, N., Massarella, J., Janssens, L., Laguardia, K.D., Leung, A.T. Journal of clinical pharmacology (2007) [Pubmed]
  9. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Lindenmaier, H., Becker, M., Haefeli, W.E., Weiss, J. Drug Metab. Dispos. (2005) [Pubmed]
  10. Introduction to steroids in the menopause. Samsioe, G. Am. J. Obstet. Gynecol. (1992) [Pubmed]
  11. Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro. Wild, M.J., Rudland, P.S., Back, D.J. J. Steroid Biochem. Mol. Biol. (1993) [Pubmed]
  12. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Jick, S.S., Jick, H. Contraception. (2006) [Pubmed]
  13. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. McGuire, J.L., Phillips, A., Hahn, D.W., Tolman, E.L., Flor, S., Kafrissen, M.E. Am. J. Obstet. Gynecol. (1990) [Pubmed]
  14. Norgestimate: a clinical overview of a new progestin. Bringer, J. Am. J. Obstet. Gynecol. (1992) [Pubmed]
  15. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Corson, S.L. Am. J. Obstet. Gynecol. (1994) [Pubmed]
  16. Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol. Lawson, J.S., Yuliano, S.E., Pasquale, S.A., Osterman, J.J. Am. J. Obstet. Gynecol. (1979) [Pubmed]
  17. Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women. Curran, M.P., Wagstaff, A.J. Drugs & aging. (2001) [Pubmed]
  18. Effects of 180 micrograms and 250 micrograms norgestimate on pituitary-ovarian function and cervical mucus. Eyong, E., Buchi, K., Elstein, M. Fertil. Steril. (1988) [Pubmed]
  19. Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro. Madden, S., Back, D.J. J. Steroid Biochem. Mol. Biol. (1991) [Pubmed]
  20. New progestogens in oral contraceptives. Runnebaum, B., Rabe, T. Am. J. Obstet. Gynecol. (1987) [Pubmed]
  21. The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterus. Killinger, J., Hahn, D.W., Phillips, A., Hetyei, N.S., McGuire, J.L. Contraception. (1985) [Pubmed]
  22. Combined oral hormone replacement therapy formulations. Mattox, J.H., Shulman, L.P. Am. J. Obstet. Gynecol. (2001) [Pubmed]
  23. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Hammond, G.L., Rabe, T., Wagner, J.D. Am. J. Obstet. Gynecol. (2001) [Pubmed]
  24. Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. Back, D.J., Houlgrave, R., Tjia, J.F., Ward, S., Orme, M.L. J. Steroid Biochem. Mol. Biol. (1991) [Pubmed]
  25. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Cibula, D., Sindelka, G., Hill, M., Fanta, M., Skrha, J., Zivny, J. Hum. Reprod. (2002) [Pubmed]
  26. Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Prifti, S., Lelle, I., Zhong, G., Strowitzki, T., Rabe, T. Gynecol. Endocrinol. (2004) [Pubmed]
  27. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Phillips, A., Hahn, D.W., McGuire, J.L. Steroids (1990) [Pubmed]
  28. Receptor binding of norgestimate--a new orally active synthetic progestational compound. Juchem, M., Pollow, K., Elger, W., Hoffmann, G., Möbus, V. Contraception. (1993) [Pubmed]
  29. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann, A. International journal of fertility and menopausal studies. (1995) [Pubmed]
  30. Disposition of norgestimate in the presence and absence of ethinyl estradiol after oral administration to humans. Weintraub, H.S., Abrams, L.S., Patrick, J.E., McGuire, J.L. Journal of pharmaceutical sciences. (1978) [Pubmed]
  31. Determination of norgestimate and ethinyl estradiol in tablets by high-performance liquid chromatography. Lane, P.A., Mayberry, D.O., Young, R.W. Journal of pharmaceutical sciences. (1987) [Pubmed]
  32. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Runnebaum, B., Grunwald, K., Rabe, T. Am. J. Obstet. Gynecol. (1992) [Pubmed]
WikiGenes - Universities